Can Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?
Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in adults with moderate to severe plaque psoriasis, highlighting meaningful skin clearance across difficult areas.
See our latest analysis for Takeda Pharmaceutical.
Together with the zasocitinib update and the recent plasma collaboration in Indonesia, Takeda Pharmaceutical’s 11.03% 1 month share price return and 35.86% 1 year total shareholder return suggest momentum has been building rather than fading.
If this psoriasis data has you thinking about where else growth stories might emerge in healthcare, it could be a good moment to scan for 7 healthcare AI stocks
Takeda Pharmaceutical now has a late stage pipeline story that is getting more attention, yet the stock still trades below analyst price targets and some estimates of intrinsic value. Is this a strong business available at a reasonable price today?
Most Popular Narrative: 9.8% Undervalued
Takeda Pharmaceutical’s most followed narrative points to a fair value of ¥6,262.69, modestly above the last close at ¥5,648, and attributes that gap to a late stage pipeline and easing legacy headwinds.
The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda's core growth and launch products to drive top line and earnings recovery going forward.
Want to see what sits behind that recovery story? The narrative leans on steady top line expansion, rising margins and a richer profit multiple. Curious how those moving parts combine into the fair value number?
Result: Fair Value of ¥6,262.69 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Takeda Pharmaceutical’s story could look very different if generic and biosimilar competition becomes more intense than expected or if key late stage pipeline assets underperform.
Find out about the key risks to this Takeda Pharmaceutical narrative.
Another View on Takeda Pharmaceutical’s Valuation
The analyst narrative suggests Takeda Pharmaceutical is modestly undervalued at ¥5,648 versus a fair value of ¥6,262.69, based on future earnings and a 32.4x P/E in 2029. Our DCF model tells a very different story, with a future cash flow value of ¥15,074.08, implying a much steeper discount. Which set of assumptions do you find more realistic?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With mixed signals across Takeda Pharmaceutical’s valuation and outlook, it makes sense to review the full picture quickly and form your own stance. To weigh the potential upside against the key concerns in one place, start by looking at the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Takeda Pharmaceutical?
If Takeda Pharmaceutical has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist now using fresh ideas surfaced by Simply Wall Street’s screeners.
- Target potential value plays by checking companies that appear mispriced on fundamentals inside the 16 high quality undervalued stocks.
- Strengthen your income stream by reviewing higher yielding candidates that show up as 43 dividend fortresses.
- Prioritize resilience by focusing on companies flagged as 53 resilient stocks with low risk scores before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com